TYK2 Protein Emerges as Key Driver of Alzheimer's Neuroinflammation

A new study has uncovered a key player in the neuroinflammation linked to Alzheimer's disease (AD). Researchers identified TYK2, a protein, as a central mediator in brains affected by TDP-43 pathology—a hallmark of certain AD cases. The findings suggest TYK2 could serve as both a treatment target and a biomarker for tracking disease progression.

The work highlights the complexity of Alzheimer's and the potential for precision medicine to tackle its varied mechanisms.

Using spatial transcriptomics, the team mapped molecular activity in AD brain tissues. They found that TYK2 becomes overactive in microglia—the brain's immune cells—when TDP-43 proteins clump together. This hyperactivity worsens tissue damage and speeds up cognitive decline.

In lab experiments, small-molecule TYK2 inhibitors reduced inflammation in microglia and shielded neurons from harm. Mice genetically modified to lack TYK2 showed fewer inflammatory markers and less neuronal death. The protein's role in activating STAT1 and STAT3 pathways—key regulators of immune and stress responses—was also confirmed. Existing JAK inhibitors, already used for other inflammatory diseases, could provide a starting point for developing TYK2-targeted AD therapies. However, no clinical trials or drug programmes currently focus on TYK2 inhibitors for Alzheimer's patients with TDP-43 pathology. Elevated TYK2 levels in patients' cerebrospinal fluid were linked to faster cognitive decline and more severe symptoms.

The study underscores TYK2's dual potential as a therapeutic target and a biomarker in Alzheimer's disease. Its involvement in neuroinflammation and cognitive decline offers a new path for precision treatments. Yet, further research is needed before TYK2 inhibitors can move from the lab to clinical testing.